Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 32.56 Billion KRW | -57.23% |
| 2022 | 38.23 Billion KRW | 17.25% |
| 2021 | 39.41 Billion KRW | 6.25% |
| 2020 | 44.75 Billion KRW | 23.28% |
| 2019 | 28.34 Billion KRW | 28.67% |
| 2018 | 25.89 Billion KRW | 169.33% |
| 2017 | 76.71 Billion KRW | -169.4% |
| 2016 | 47.37 Billion KRW | 156.45% |
| 2015 | 18 Billion KRW | -2.94% |
| 2014 | 18.27 Billion KRW | 34.61% |
| 2013 | 13.8 Billion KRW | -36.72% |
| 2012 | 21.68 Billion KRW | -34.89% |
| 2011 | 33.24 Billion KRW | 29.49% |
| 2010 | 26.6 Billion KRW | -3.6% |
| 2009 | 28.5 Billion KRW | -39.74% |
| 2008 | 45.32 Billion KRW | 22.06% |
| 2007 | 36.79 Billion KRW | 109.11% |
| 2006 | 17.46 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 9.27 Billion KRW | -5.49% |
| 2024 Q1 | 10.68 Billion KRW | 145.11% |
| 2023 Q2 | 46.17 Billion KRW | -12.25% |
| 2023 Q1 | 52.62 Billion KRW | 993.02% |
| 2023 Q4 | -1.56 Billion KRW | -103.48% |
| 2023 Q3 | 45.02 Billion KRW | -2.5% |
| 2023 FY | - KRW | -57.23% |
| 2022 Q1 | 12.44 Billion KRW | 21.68% |
| 2022 Q3 | 12.75 Billion KRW | -8.13% |
| 2022 Q4 | 4.81 Billion KRW | -62.25% |
| 2022 FY | - KRW | 17.25% |
| 2022 Q2 | 13.88 Billion KRW | 11.55% |
| 2021 Q1 | 8.52 Billion KRW | -12.71% |
| 2021 FY | - KRW | 6.25% |
| 2021 Q2 | 11.57 Billion KRW | 35.67% |
| 2021 Q3 | 7.11 Billion KRW | -38.55% |
| 2021 Q4 | 10.22 Billion KRW | 43.85% |
| 2020 Q4 | 9.77 Billion KRW | -4.63% |
| 2020 Q3 | 10.24 Billion KRW | 10.27% |
| 2020 Q2 | 9.29 Billion KRW | 56.72% |
| 2020 FY | - KRW | 23.28% |
| 2020 Q1 | 5.92 Billion KRW | -65.19% |
| 2019 Q4 | 17.02 Billion KRW | 412.29% |
| 2019 Q2 | 2.59 Billion KRW | -53.88% |
| 2019 Q1 | 5.62 Billion KRW | 0.0% |
| 2019 FY | - KRW | 28.67% |
| 2019 Q3 | 3.32 Billion KRW | 28.03% |
| 2018 Q4 | - KRW | -100.0% |
| 2018 FY | - KRW | 169.33% |
| 2018 Q2 | 3.76 Billion KRW | -54.25% |
| 2018 Q1 | 8.22 Billion KRW | 115.87% |
| 2018 Q3 | 4.32 Billion KRW | 14.9% |
| 2017 Q3 | 5.08 Billion KRW | -29.12% |
| 2017 FY | - KRW | -169.4% |
| 2017 Q4 | -51.82 Billion KRW | -1118.67% |
| 2017 Q1 | 7.52 Billion KRW | -70.8% |
| 2017 Q2 | 7.17 Billion KRW | -4.59% |
| 2016 FY | - KRW | 156.45% |
| 2016 Q1 | 9.7 Billion KRW | 70.65% |
| 2016 Q2 | 5.34 Billion KRW | -44.98% |
| 2016 Q3 | 5.01 Billion KRW | -6.07% |
| 2016 Q4 | 25.75 Billion KRW | 413.54% |
| 2015 Q1 | 5.29 Billion KRW | 11.55% |
| 2015 Q4 | 5.68 Billion KRW | 174.03% |
| 2015 Q3 | 2.07 Billion KRW | -57.98% |
| 2015 Q2 | 4.93 Billion KRW | -6.77% |
| 2015 FY | - KRW | -2.94% |
| 2014 Q2 | 4.65 Billion KRW | -14.07% |
| 2014 Q1 | 5.41 Billion KRW | 367.25% |
| 2014 FY | - KRW | 34.61% |
| 2014 Q4 | 4.74 Billion KRW | 27.62% |
| 2014 Q3 | 3.72 Billion KRW | -20.07% |
| 2013 Q3 | 535.74 Million KRW | -87.58% |
| 2013 FY | - KRW | -36.72% |
| 2013 Q1 | 7.76 Billion KRW | 81.12% |
| 2013 Q2 | 4.31 Billion KRW | -44.44% |
| 2013 Q4 | 1.15 Billion KRW | 116.45% |
| 2012 Q4 | 4.28 Billion KRW | -29.4% |
| 2012 Q1 | 5.27 Billion KRW | 28.84% |
| 2012 Q2 | 6.13 Billion KRW | 16.39% |
| 2012 FY | - KRW | -34.89% |
| 2012 Q3 | 6.07 Billion KRW | -1.01% |
| 2011 FY | - KRW | 29.49% |
| 2011 Q2 | 8.69 Billion KRW | -19.62% |
| 2011 Q4 | 4.09 Billion KRW | -41.19% |
| 2011 Q1 | 10.81 Billion KRW | 11.78% |
| 2011 Q3 | 6.95 Billion KRW | -19.98% |
| 2010 Q3 | 5.15 Billion KRW | 21.02% |
| 2010 Q4 | 9.67 Billion KRW | 87.87% |
| 2010 Q1 | 6.73 Billion KRW | 0.0% |
| 2010 FY | - KRW | -3.6% |
| 2010 Q2 | 4.25 Billion KRW | -36.84% |
| 2009 Q2 | 9.99 Billion KRW | -36.99% |
| 2009 Q1 | 15.86 Billion KRW | 63.0% |
| 2009 FY | - KRW | -39.74% |
| 2009 Q3 | 8.8 Billion KRW | -11.91% |
| 2008 FY | - KRW | 22.06% |
| 2008 Q3 | 8.65 Billion KRW | -15.12% |
| 2008 Q4 | 9.73 Billion KRW | 12.43% |
| 2008 Q2 | 10.19 Billion KRW | -22.93% |
| 2008 Q1 | 13.23 Billion KRW | 63.44% |
| 2007 Q4 | 8.09 Billion KRW | -2.51% |
| 2007 FY | - KRW | 109.11% |
| 2007 Q2 | 6.78 Billion KRW | 0.0% |
| 2007 Q3 | 8.3 Billion KRW | 22.42% |
| 2006 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -570.219% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 76.966% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 150.849% |
| HANDOK Inc. | 35.06 Billion KRW | 7.144% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 3241.256% |
| Yuhan Corporation | 127.43 Billion KRW | 74.448% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 13.218% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 250.139% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 89.929% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -552.492% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -115.379% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -851.819% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -619.368% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 8.242% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -570.219% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 276.276% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -396.745% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 166.058% |
| JW Holdings Corporation | 187.88 Billion KRW | 82.669% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 163.561% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 88.52% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 63.505% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 187.845% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -146.499% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -175.295% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -74.547% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -570.219% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 40.768% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 80.255% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 63.505% |
| Yuhan Corporation | 127.43 Billion KRW | 74.448% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 2.732% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -325.65% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 57.728% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 63.505% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 11.118% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 53.996% |
| CKD Bio Corp. | -1.63 Billion KRW | 2097.093% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 34.606% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 11.543% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 187.845% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 47.721% |
| Boryung Corporation | 114.28 Billion KRW | 71.509% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 206.52% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -115.379% |
| JW Lifescience Corporation | 50.82 Billion KRW | 35.939% |